Market Cap | 6.64M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.14M | Forward P/E | 0.71 | EPS next Y | - | 50D Avg Chg | -27.00% |
Sales | 22.36M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 59.10% | 52W High Chg | -92.00% |
Recommedations | 2.00 | Quick Ratio | 0.03 | Shares Outstanding | 44.57M | 52W Low Chg | 22.00% |
Insider Own | 18.05% | ROA | -4.40% | Shares Float | 37.29M | Beta | 1.10 |
Inst Own | 10.38% | ROE | - | Shares Shorted/Prior | 2M/439.68K | Price | 0.18 |
Gross Margin | 23.28% | Profit Margin | -5.11% | Avg. Volume | 5,130,451 | Target Price | - |
Oper. Margin | -208.39% | Earnings Date | Oct 2 | Volume | 1,446,606 | Change | -8.29% |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
HC Wainwright & Co. | Buy | Nov 6, 23 |
HC Wainwright & Co. | Buy | Oct 20, 23 |
HC Wainwright & Co. | Buy | Jan 26, 23 |
Maxim Group | Hold | Aug 16, 22 |
HC Wainwright & Co. | Buy | Jul 20, 21 |
HC Wainwright & Co. | Buy | May 15, 20 |
Roth Capital | Buy | Feb 19, 20 |
HC Wainwright & Co. | Buy | Dec 30, 19 |
Northcoast Research | Outperform | Sep 10, 18 |